Transaction DateRecipientSharesTypePriceValue
23rd November 2020Advisors Llc Perceptive500,000Open or private purchase$12.85$6,425,000.00
27th October 2020Advisors Llc Perceptive3,000,000Open or private purchase$10.00$30,000,000.00
21st October 2020Advisors Llc Perceptive43,195Open or private purchase$10.09$435,837.55
20th October 2020Advisors Llc Perceptive114,100Open or private purchase$10.00$1,141,000.00
22nd September 2020Advisors Llc Perceptive1,644,785Conversion of derivative$0.00
22nd September 2020Advisors Llc Perceptive1,058,824Open or private purchase$17.00$18,000,008.00
15th September 2020Advisors Llc Perceptive2,911,764Open or private purchase$4.25$12,374,997.00
14th September 2020Advisors Llc Perceptive400,000Open or private purchase$40.00$16,000,000.00
14th September 2020Advisors Llc Perceptive1,800,000Open or private purchase$11.00$19,800,000.00
10th September 2020Advisors Llc Perceptive200,000Open or private purchase$11.24$2,248,000.00
Kadmon Holdings
Kadmon Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Kadmon Holdings, Inc. is a biopharmaceutical company. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir and Abacavir.


Ticker: KDMN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1557142
Employees: 115
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $170 M (0%)
Inventory, Net: $116 Th (0%)
Assets, Current: $185 M (0%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $22 Th (-78%)
Assets: $213 M (0%)
Accounts Payable, Current: $12 M (29%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $30 M (4%)
Liabilities: $50 M (1%)
Common Stock, Value, Issued: $171 Th (6%)
Common Stock, Shares, Issued: $171 M (7%)
Retained Earnings (Accumulated Deficit): $391 M (0%)
Stockholders' Equity (Parent): $163 M (-1%)
Liabilities and Equity: $213 M (0%)
Gross Margin: $336 Th (-94%)
Research and Development: $17 M (-43%)
Operating Income/Loss: $27 M (-37%)
Other Income, net: $232 Th (-98%)
EPS (basic): $0.17 (0%)
EPS (diluted): $0.17 (0%)